<DOC>
	<DOCNO>NCT02092155</DOCNO>
	<brief_summary>Some patient tunnel pleural catheter pleural fluid ( water around lung ) return time ( pleurodesis ) . The purpose study understand investigator predict achieve pleurodesis occur study pleural effusion .</brief_summary>
	<brief_title>Biomarker Levels During Indwelling Pleural cAtheter Sample Testing</brief_title>
	<detailed_description>An alternative emerging treatment malignant pleural effusion placement chronic indwell pleural catheter . Tunneled pleural catheter ( TPC ) ideal treatment malignant pleural effusion ( MPE ) associate trap non-expandable lung sufficient visceral parietal pleura apposition chemical pleurodesis . Transforming growth factor-Beta 1 ( TGF-β ) profibrotic cytokine , potent inducer Plasminogen activator inhibitor-1 ( PAI-1 ) human pleural mesothelial cell . PAI-1 inhibits protease-dependent fibrinolytic activity along TGF-β , concentration increase exudative tuberculous pleural effusion . TGF-β level pleural fluid show correlate pleural thickness tuberculosis pleurisy empyema rabbit . TGF-β multifunctional cytokine primarily produce mesothelial cell pleural space , also originate lung parenchymal macrophage migrate pleural space . In human , TGF-β consist three isoforms ( TGF-β1 , TGF-β2 , TGF-β3 ) . They share many biological activity action cell qualitatively similar case . TGF-β stimulates extracellular matrix production study support TGF-β over-production key regulator pleural fibrosis chemical pleurodesis . Moreover , TGF-β signal production PAI-1 clearly note human mesothelial cell different origin . Different inflammatory stimuli pleural space include malignancy infection may activate TGF-β up-regulation enhance production turn result PAI-1 expression .</detailed_description>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Pleural Effusion , Malignant</mesh_term>
	<criteria>Inclusion criterion : Pleural effusion ( etiology fulfil one follow criterion ) : 1 . Malignant effusion confirm cytology pleural biopsy 2. exudative effusion set know malignancy identifiable cause 3 . Malignant effusion due tumor historically rapidly responsive systemic therapy ( small cell lung cancer , hematological malignancy ) include refractory standard chemotherapy 18 year age Symptoms shortness breath , cough , chest fullness/chest discomfort Demonstration symptomatic improvement therapeutic thoracentesis Recurrent pleural effusion therapeutic thoracentesis Capacity provide inform consent Exclusion criterion : Projected life expectancy le 30 day . Radiographic evidence trap lung persistent lung collapse failure majority ( &gt; 50 % ) lung reexpand follow drainage pleural effusion Previous lobectomy pneumonectomy affected side Patient receive intrapleural chemotherapy Chylothorax pleural effusion triglyceride level &gt; 110 mg/dl chylomicron lipoprotein analysis , commonly due trauma/obstruction thoracic duct Parapneumonic effusion pleural effusion associate pneumonia Empyema infect pleural space define purulent pleural fluid , positive gram stain , positive culture Inability adequately perform pleural drainage home Uncorrectable bleed disorder Skin infection site intend catheter insertion Pregnant woman detect spot urine test prior procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>